Back to results
US 12,343,355 B2Granted
Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
AssigneeAbbott Laboratories
InventorsJoMay Chow, Steven R. Davis, Rachael Buck, Geralyn O. Duska-McEwen, Hawley K. Linke
Life of this patent
Estimating the term…
Abstract
Disclosed are methods of reducing the incidence of necrotizing enterocolitis in an infant, toddler, or child using nutritional compositions including human milk oligosaccharides. The nutritional compositions including the human milk oligosaccharides are effective in reducing inflammation and the incidence of inflammatory diseases.
Claims22
A shelf stable synthetic formula comprising:
- from about 0.2 mg/mL to about 20 mg/mL of an oligosaccharide blend, wherein the oligosaccharide blend comprises a first human milk oligosaccharide, 2′-fucosyllactose,
- from about 0.001 g/L to about 1 g/L of a long chain polyunsaturated fatty acid component comprising docosahexaenoic acid and arachidonic acid, wherein the ratio of docosahexaenoic acid to arachidonic acid is from about 1:4 to about 1:2;
- from about 42 mg/L to about 200 mg/L of a monomeric monophosphate nucleotide component;
- and
- lactodifucotetraose;
- wherein the synthetic formula is shelf stable for at least 3 months.
3 more elements
A shelf stable synthetic formula comprising:
- from about 0.2 mg/mL to about 20 mg/mL of an oligosaccharide blend, wherein the oligosaccharide blend comprises a first human milk oligosaccharide, 2′-fucosyllactose,
- from about 0.001 g/L to about 1 g/L of a long chain polyunsaturated fatty acid component comprising docosahexaenoic acid and arachidonic acid, wherein the ratio of docosahexaenoic acid to arachidonic acid is from about 1:4 to about 1:2;
- from about 42 mg/L to about 200 mg/L of a monomeric monophosphate nucleotide component, wherein the monomeric monophosphate nucleotide component comprises at least one monomeric monophosphate nucleotide that is a free acid and at least one other monomeric monophosphate nucleotide that is a salt;
- wherein the synthetic formula is shelf stable for at least 3 months.
1 more element
Dependencies are inferred from the claim text.